Characteristics of procalcitonin in hospitalized COVID-19 patients and clinical outcomes of antibiotic use stratified by procalcitonin levels
Tóm tắt
We examined the characteristics of pro-calcitonin (PCT) in hospitalized COVID-19 patients (cohort 1) and clinical outcomes of antibiotic use stratified by PCT in non-critically ill patients without bacterial co-infection (cohort 2). Retrospective reviews were performed in adult, hospitalized COVID-19 patients during March–May 2020. For cohort 1, we excluded hospital transfers, renal disease and extra-pulmonary infection without isolated pathogen(s). For cohort 2, we further excluded microbiologically confirmed infection, ‘do not resuscitate ± do not intubate’ status, and intensive care unit (ICU). For cohort 1, PCT was compared between absent/low-suspicion and proven bacterial co-infections. Factors associated with elevated PCT and sensitivity/specificity/PPV/NPV of PCT cutoffs for identifying bacterial co-infections were explored. For cohort 2, clinical outcomes including mechanical ventilation within 5 days (MV5) were compared between the antibiotic and non-antibiotic groups stratified by PCT ≥ 0.25 µg/L. Nine hundred and twenty four non-ICU and 103 ICU patients were included (cohort 1). The median PCT was higher in proven vs. absent/low-suspicion of bacterial co-infection. Elevated PCT was significantly associated with proven bacterial co-infection, ICU status and oxygen requirement. For PCT ≥ 0.25 µg/L, sensitivity/specificity/PPV/NPV were 69/65/6.5/98% (non-ICU) and 75/33/8.6/94% (ICU). For cohort 2, 756/1305 (58%) patients were included. Baseline characteristics were balanced between the antibiotic and non-antibiotic groups except PCT ≥ 0.25 µg/L (antibiotic:non-antibiotic = 59%:24%) and tocilizumab use (antibiotic:non-antibiotic = 5%:2%). 23% (PCT < 0.25 µg/L) and 58% (PCT ≥ 0.25 µg/L) received antibiotics. Antibiotic group had significantly higher rates of MV5. COVID-19 severity inferred from ICU status and oxygen requirement as well as the presence of bacterial co-infections were associated with elevated PCT. PCT showed poor PPV and high NPV for proven bacterial co-infections. The use of antibiotics did not show improved clinical outcomes in COVID-19 patients with PCT ≥ 0.25 µg/L outside of ICU when bacterial co-infections are of low suspicion.
Tài liệu tham khảo
citation_journal_title=J Clin Endocrionol Metab; citation_title=Procalcitonin increase after endotoxin injection in normal subjects; citation_author=P Dandona, D Nix, MF Wilson; citation_volume=79; citation_issue=5; citation_publication_date=1994; citation_pages=1605-1608; citation_id=CR1
citation_journal_title=Am J Respir Crit Care Med; citation_title=Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia; citation_author=M Christ-Crain, D Stolz, R Bingisser; citation_volume=174; citation_publication_date=2006; citation_pages=84-93; citation_doi=10.1164/rccm.200512-1922OC; citation_id=CR2
citation_journal_title=JAMA; citation_title=Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections-the ProHOSP randomized controlled trial; citation_author=P Schuetz, M Christ-Crain, R Thomann; citation_volume=302; citation_issue=10; citation_publication_date=2009; citation_pages=1059-1066; citation_doi=10.1001/jama.2009.1297; citation_id=CR3
citation_journal_title=Lancet; citation_title=Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial; citation_author=M Christ-Crain, D Jaccard-Stolz, R Bingisser; citation_volume=363; citation_publication_date=2004; citation_pages=600-607; citation_doi=10.1016/S0140-6736(04)15591-8; citation_id=CR4
citation_journal_title=Lancent; citation_title=Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicenter randomized controlled trial; citation_author=L Bouadma, CE Luyt, F Tubach; citation_volume=375; citation_issue=9713; citation_publication_date=2010; citation_pages=463-474; citation_doi=10.1016/S0140-6736(09)61879-1; citation_id=CR5
citation_journal_title=Int J Antimicrob Agents; citation_title=Procalcitonin levels in COVID-19 patients; citation_author=R Hu, C Han, S Pei; citation_volume=56; citation_publication_date=2020; citation_doi=10.1016/j.ijantimicag.2020.106051; citation_id=CR6
citation_journal_title=J Glob Antimicrob Resist; citation_title=Procalcitonin as an antibiotic stewardship tool in COVID-19 patients in the intensive care unit; citation_author=L Heesom, L Rehnberg, M Nasim-Mohi; citation_volume=22; citation_publication_date=2020; citation_pages=782-784; citation_doi=10.1016/j.jgar.2020.07.017; citation_id=CR7
citation_journal_title=Lancet; citation_author=N Chen, M Zhou, X Dong; citation_volume=395; citation_publication_date=2020; citation_pages=507-513; citation_doi=10.1016/S0140-6736(20)30211-7; citation_id=CR8
citation_journal_title=JAMA; citation_author=D Wang, B Hu, C Hu; citation_volume=323; citation_publication_date=2020; citation_pages=1061-1069; citation_doi=10.1001/jama.2020.1585; citation_id=CR9
citation_journal_title=Infect Control Hosp Epidemiol; citation_title=The role of procalcitonin in antibiotic decision-making in COVID-19 infection; citation_author=V Fabre, S Karaba, J Amoah; citation_publication_date=2021; citation_doi=10.1017/ice.2021.175; citation_id=CR10
citation_journal_title=Antimicrob Agents Chemother; citation_title=Limited utility of procalcitonin in identifying community-associated bacterial infections in patients presenting with Coronavirus disease 2019; citation_author=M May, M Chang, D Dietz; citation_volume=65; citation_issue=4; citation_publication_date=2021; citation_pages=e02167-e2220; citation_doi=10.1128/AAC.02167-20; citation_id=CR11
citation_journal_title=Lancet; citation_author=F Zhou, T Yu, R Du; citation_volume=395; citation_publication_date=2020; citation_pages=1054-1062; citation_doi=10.1016/S0140-6736(20)30566-3; citation_id=CR12
citation_journal_title=N Engl J Med; citation_title=Clinical characteristics of Covid-19 in New York city; citation_author=P Goyal, JJ Choi, LC Pinheiro; citation_volume=382; citation_issue=24; citation_publication_date=2020; citation_pages=2372-2374; citation_doi=10.1056/NEJMc2010419; citation_id=CR13
citation_journal_title=Clin Chim Acta; citation_title=Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis; citation_author=G Lippi, M Plebani; citation_volume=505; citation_issue=190–191; citation_publication_date=2020; citation_pages=190-191; citation_doi=10.1016/j.cca.2020.03.004; citation_id=CR14
citation_journal_title=Clin Med; citation_title=Procalcitonin for patient stratification and identification of bacterial co-infection in COVID-19; citation_author=J Han, T Gatheral, C Williams; citation_volume=20; citation_publication_date=2020; citation_doi=10.7861/clinmed.Let.20.3.3; citation_id=CR15
citation_journal_title=Clin Infect Dis Clin Infect Dis; citation_title=Bacterial and fungal co-infection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing; citation_author=TM Rawson, LSP Moore, N Zhu; citation_volume=71; citation_publication_date=2020; citation_pages=2459-2468; citation_doi=10.1093/cid/ciaa530; citation_id=CR16
citation_journal_title=Clin Microbiol Infect; citation_title=Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis; citation_author=BJ Langford, M So, S Raybardhan; citation_volume=27; citation_publication_date=2021; citation_pages=520-531; citation_doi=10.1016/j.cmi.2020.12.018; citation_id=CR17
citation_journal_title=Trends Microbiol; citation_title=Bacterial coinfections in coronavirus disease 2019; citation_author=LF Westblade, MS Simon, MJ Satlin; citation_volume=29; citation_issue=10; citation_publication_date=2021; citation_pages=930-941; citation_doi=10.1016/j.tim.2021.03.018; citation_id=CR18
citation_journal_title=J Infect; citation_title=Co-infections in people with COVID-19: a systematic review and meta-analysis; citation_author=L Lansbury, B Lim, V Baskaran; citation_volume=81; citation_publication_date=2020; citation_pages=266-275; citation_doi=10.1016/j.jinf.2020.05.046; citation_id=CR19
citation_journal_title=Crit Care; citation_title=Biomarkers for antimicrobial stewardship: a reappraisal in COVID-19 times?; citation_author=M Berkel, M Kox, T Frenzel; citation_volume=24; citation_issue=1; citation_publication_date=2020; citation_pages=600; citation_doi=10.1186/s13054-020-03291-w; citation_id=CR20
Wang TZ, Simon MS, Mazur S, Lyman L, Calfee DP. Procalcitonin in the management of lower respiratory tract infections and sepsis [master’s thesis]. NewYork-Presbyterian/Weill Cornell Medical Center; 2020. 34 p.
citation_journal_title=Intesive Care Med; citation_title=Procalcitonin: a marker to clearly differentiate systemic inflammatory response syndrome and sepsis in the critically ill patient?; citation_author=E Giamarellos-Bourboulis, A Mega, P Grecka; citation_volume=28; citation_issue=9; citation_publication_date=2002; citation_pages=1351-1356; citation_doi=10.1007/s00134-002-1398-z; citation_id=CR22
COVID-19 Treatment GUIDELINES PANEl. Coronavirus disease 2019 (COVID-19) Treatment guidelines. National Institutes of Health. Available at
https://www.covid19treatmentguidelines.nih.gov/
. Accessed April 16, 2021.